Psilocybin use and psychosis-related outcomes in a large observational dataset show limited population-level association amid important clinical cautions

Psilocybin use shows limited population-level association with psychosis-related outcomes in a large observational dataset, while still warranting caution for people with individual vulnerability. The central finding points away from a strong broad link between psilocybin exposure and psychosis across the general population, but it does not establish safety for everyone or rule out rare adverse reactions. Clinical relevance turns on subgroup risk, study design, and outcome definition. Observational data can detect broad patterns, yet they cannot fully separate psilocybin effects from preexisting mental health factors, polysubstance use, dose variability, setting, or reporting bias. People with personal or family histories of psychotic disorders remain a key concern. The wider implication is that public debate and policy need to distinguish between population averages and high-risk individuals. Research on psychedelic safety benefits from more precise screening, prospective designs, and clearer characterization of dose, context, and co-occurring psychiatric risk.